GlassScriptPhysician profile
Sarah A Hanson
NPI 1427212737
$2,361.38
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $60.16 · 2021: $230 · 2022: $338 · 2023: $701 · 2024: $405 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $566.68 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Oyster Point Pharma, INC. | $507.39 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $288.64 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $167.95 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $140.85 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Aerie Pharmaceuticals, INC. | $87.10 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $80.11 | 2023 | |
| Rxsight INC | $77.41 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $76.88 | 2019-2025 | |
| Dompe US, INC. | $63.19 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.41 | 2020-2021 | |
| Horizon Therapeutics Plc | $53.92 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $40.70 | 2021 | |
| Ocular Therapeutix, INC. | $36.91 | 2023-2025 | Dextenza |
| Abbvie INC. | $35.63 | 2022-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $22.55 | 2025 | Iyuzeh |
| Halozyme INC | $21.63 | 2023 | |
| Eyevance Pharmaceuticals LLC | $16.91 | 2021 | |
| Shire North American Group INC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.